Capturing the primordial Kras mutation initiating urethane carcinogenesis

Li, Siqi; MacAlpine, David M.; Counter, Christopher M.

doi:10.1038/s41467-020-15660-8

Download PDF

Article
Open access
Published: 14 April 2020

Capturing the primordial Kras mutation initiating urethane carcinogenesis

Nature Communications volume 11, Article number: 1800 (2020) Cite this article

3483 Accesses
22 Citations
2 Altmetric
Metrics details

Subjects

Oncogenes

Abstract

The environmental carcinogen urethane exhibits a profound specificity for pulmonary tumors driven by an oncogenic Q₆₁L/R mutation in the gene Kras. Similarly, the frequency, isoform, position, and substitution of oncogenic RAS mutations are often unique to human cancers. To elucidate the principles underlying this RAS mutation tropism of urethane, we adapted an error-corrected, high-throughput sequencing approach to detect mutations in murine Ras genes at great sensitivity. This analysis not only captured the initiating Kras mutation days after urethane exposure, but revealed that the sequence specificity of urethane mutagenesis, coupled with transcription and isoform locus, to be major influences on the extreme tropism of this carcinogen.

Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF

Article 27 March 2024

Sandi Radko-Juettner, Hong Yue, … Charles W. M. Roberts

An atlas of epithelial cell states and plasticity in lung adenocarcinoma

Article Open access 28 February 2024

Guangchun Han, Ansam Sinjab, … Humam Kadara

Chromatin accessibility profiling by ATAC-seq

Article 27 April 2022

Fiorella C. Grandi, Hailey Modi, … M. Ryan Corces

Introduction

Exposure of mice to the environmental carcinogen urethane primarily induces tumors in one organ (lung) with a single driver mutation in only one of the three Ras genes (Kras), at one position (Q₆₁), with one substitution (L or R depending on the mouse strain)^1,2,3,4,5. This extreme RAS mutation tropism is rather remarkable considering that oncogenic Ras is well known to cause a host of cancers in the mouse beyond the lungs⁶. Further, there are 57 possible point mutations generating 54 known or potentially oncogenic substitutions among the three Ras genes (Hras, Nras, and Kras) at the three major oncogenic positions (G₁₂, G₁₃, and Q₆₁) from a total of six possible oncogenic amino acids (V, D, C, S, R, A at G₁₂/G₁₃ and L, R, K, H, E, P at Q₆₁)⁷. Capturing the mutations arising immediately after urethane exposure in normal tissues in vivo would greatly inform the underlying mechanism by which this carcinogen induces one tumor type driven by an incredibly specific Ras mutation.

The challenge of detecting mutations early lies in the extremely low rate of urethane mutagenesis in vivo, which ranges from 5 to 100 × 10⁻⁶ or 1 mutant per 0.1 to 2 × 10⁵ templates^3,8. This rate is significantly lower than the detection limit of conventional next generation sequencing (NGS)⁹, which varies from 1 to 10 × 10⁻³ or 1 mutant per 100 to 1000 templates. Various techniques have been developed to lower the error rate of NGS^10,11, but improvements are still limited by mutations arising during early PCR steps and data recovery efficiency¹². The recently developed error-corrected, high-throughput maximum-depth sequencing (MDS) method overcomes these limitations, identifying ultra-rare (1 × 10⁻⁶, 1 mutant per 10⁶ templates) antibiotic-resistance mutations arising in bacteria populations¹³. We thus sought to adopt this assay for the much larger mammalian genome to capture the initiating Kras mutation induced by urethane in vivo to elucidate the principles underpinning the extreme selectivity of this carcinogenic process.

By adapting MDS for the mammalian genome, we capture the dominant initiating Kras^Q61L mutation in the lungs of mice immediately following urethane exposure. Further, we show that the substitution and position tropism of urethane can be largely ascribed to the specificity of this carcinogen for CAN➙CTN mutations, which generates the oncogenic Q₆₁L mutation in Kras. The same mutations were also captured in Hras, arguing that these mutations are not sufficient to induce tumorigenesis, which speaks to the isoform tropism of urethane. Last, in terms of tissue tropism, oncogenic Ras mutations were generally undetectable in other organs tested, which we suggest is linked to the transcriptional status of genes. Collectively, these finding indicate that RAS mutation tropism is a multifactorial process, which may inform similar RAS mutation patterns observed in human cancers.

Results

Adapting MDS to the mammalian genome

A barrier to detecting initiating mutations in Kras at the time they occur in vivo after urethane exposure is that the mutation rate of this carcinogen is well below the detection limit of NGS. To overcome this limitation, we turned to the error-corrected, high-throughput sequencing approach of MDS, which recovered mutants in bacteria at a frequency as low as 1 × 10⁻⁶ or 1 mutant per 10⁶ templates¹³. The key steps of MDS are first, synthesis of unique barcodes onto one strand of a genomic region-of-interest, second, linear amplification to obtain multiple direct copies of the barcoded genomic DNA, third, exponential amplification to obtain families of PCR products sharing the same barcode, and fourth, ultra-deep sequencing of millions of barcode families from the single region-of-interest¹³. Bona fide mutations are differentiated from PCR and sequencing errors by virtue of being detected in all members of one barcode family¹³. The challenge of adapting MDS to the mammalian genome is maintaining the recovery of a sufficient number of analyzable barcode families (with at least two or three members) in a genome that is three orders of magnitude larger in size and weight^14,15. To this end, we optimized assay conditions (see Methods) for mammalian Kras (Supplementary Fig. 1a) and barcode recovery (Supplementary Table 1). To validate the sensitivity of this mammalian version of MDS, we generated a panel of Kras-mutant plasmids, each comprised of Kras cDNA with a unique set of co-occurring double or triple mutations in the region encoded by exon 1 and/or exon 2 (Supplementary Table 2). Each was spiked at specific concentrations into genomic DNA isolated from mouse embryonic fibroblasts (MEFs) or murine lungs to benchmark different levels of sensitivity. As the error rates of PCR and sequencing are unlikely to give the same two or three exact improper base calls, the actual frequency of mutants present in the sample was estimated by calculating the frequency of barcode families with the pre-engineered co-occurring mutations. The frequency of mutations determined by MDS was then compared against the aforementioned actual frequency. Using this approach, we demonstrated that MDS adapted for the transcribed strand of Kras exon 1 detected mutations at a sensitivity of 5 × 10⁻⁷ or 1 mutant per 2 × 10⁶ templates (Fig. 1a, Supplementary Fig. 1b, and Supplementary Table 2). We further validated the sensitivity of the MDS assay adapted for the non-transcribed strand of Kras exon 2 in the same fashion (Supplementary Fig. 1c and Supplementary Table 2). Thus, MDS optimized for mammalian genomic DNA detects mutations at a sensitivity potentially 20,000 times greater than conventional NGS.

**Fig. 1: MDS detects ultra-rare mutations induced by the carcinogen urethane.**

Capturing the initiating oncogenic mutation in Kras

Urethane induces pulmonary tumors driven by a Kras^Q61L/R oncogenic mutation^1,3,4,5, exemplifying the selectivity of this carcinogen at the level of tissue, isoform, position, and substitution. To elucidate the processes behind this RAS mutation tropism, we exposed A/J mice to urethane or the vehicle PBS via three daily intraperitoneal injections. After 1, 2, 3, and 4 weeks, genomic DNA was isolated from the lungs of four to seven mice from each condition. The non-transcribed strand of exon 2 of the endogenous Kras gene was then sequenced by MDS. To ensure abundant depth for mutant recovery and the accuracy of detected mutation frequency, samples with <1.5 × 10⁵ barcodes were excluded from analysis. For the remaining samples (barcode recovery listed in Supplementary Data 1), mutation frequencies were summed by either nucleotide position or substitution type, normalized to control PBS, log₁₀ transformed, and then plotted as a heatmap (Fig. 1b, c). This analysis identified the well-established^1,3,4,5 oncogenic L (and to a lesser extent R) mutation at codon Q₆₁ preferentially in the urethane, but not PBS cohort of mice, as early as 1 week after exposure to this carcinogen. Consistent with being initiating events, these mutations expanded over time indicative of tumor growth (Fig. 1b and Supplementary Data 2), although a longer time course would formally confirm a tumorigenic identity. We also independently confirm by droplet digital PCR¹⁶ the presence of the Q₆₁L mutation 4 week post urethane exposure at a frequency similar to that determined by MDS (Supplementary Fig. 1d). We thus capture and confirm the primordial initiating oncogenic mutation in Kras within days of exposure to urethane.

Substitution tropism

Previous whole-exome sequencing of urethane-induced tumors revealed a strong bias toward A>T/G substitutions³, consistent with ethenodeoxyadenosine adducts forming in vivo after urethane exposure^17,18. These substitutions were also detected in Kras by MDS at a high frequency, although A>T transversions were far more common than A>G transitions (Fig. 1c). In agreement with this bias, CA₁₈₂A➙CTA gives rise to the dominant Q₆₁L oncogenic mutation in tumors of the A/J strain of mice exposed to urethane, while CA₁₈₂A➙CGA gives rise to the rarer Q₆₁R oncogenic mutation^1,5. Still, the overall A/T content of murine genome¹⁵ is about 58%, and A>T/G substitutions represents two-thirds of the possible base changes for this nucleotide. As such, this mutagenic signature is rather general compared with the extreme specificity of the initiating mutation. Further analysis of the mutation signature, using the log₁₀-transformed mutation frequencies of individual substitutions, revealed that the most prominent substitution detected by MDS in the lungs of mice after urethane (but not PBS) exposure at all time points was an A>T transversion within the context of a 5ʹ C and 3ʹ any nucleotide, namely a CAN trinucleotide (Fig. 1d, Supplementary Fig. 2a, b, and Supplementary Data 2, 3). In agreement, a 5ʹ C was favored to some extent for A>T transversions in previous whole-exome sequencing of urethane-induced lung tumors³. The frequency of CAN➙CTN mutations recovered in the urethane-exposed cohort remained constant over time in all but one case; CA₁₈₂A➙CTA encoding the oncogenic Q₆₁L mutation expanded at subsequent time points ostensibly due to tumor growth (Fig. 1e). The same was true for the second most prominent urethane-specific substitution detected by MDS, an A>G transition preceded by 5ʹ C (Supplementary Fig. 2b), where again CA₁₈₂A➙CGA that gives rise the rarer Q₆₁R oncogenic mutation^1,5 expanded over time (Supplementary Fig. 2c). Substitutions other than CA₁₈₂A➙CT/GA at codon 61 were rarely detected 1 week after urethane exposure (Fig. 1f), even though all the possible missense mutations at this codon generated by a single-nucleotide substitution (Q₆₁L, R, K, E, P, and H) have been reported in human cancers in the COSMIC database¹⁹. As such, an A>T/G substitution preceded by C greatly increases the specificity of urethane mutations for codon 61, reducing the number of potential non-synonymous changes in both strands of the murine Kras gene by fivefold, from 616 to 120. The selectivity of these two substitutions after urethane exposure thus appears to be a major contributing factor to the substitution bias toward Q₆₁L/R mutations in Kras.

Position tropism

This bias of urethane for (C)A>T/G substitutions similarly argues against mutations arising at an appreciable level in codons 12 (G₃₄GT) or 13 (G₃₇GC) in exon 1, as neither fit the CAN pattern in either strand orientation. Related to this, despite the fact that oncogenic mutations at G₁₂, and to a lesser extent G₁₃, occur frequently in human cancers¹⁹ and when introduced into the lungs of mice are tumorigenic to varying degrees²⁰, they are rarely recovered from urethane-induced tumors³. We therefore sequenced the transcribed strand of exon 1 of Kras by MDS from genomic DNA isolated from the lungs of mice 1, 2, 3, and 4 weeks after exposure to urethane or PBS. To overcome interference from strand-specific background (see Methods), we also sequenced the non-transcribed strand of exon 1 of Kras by MDS from the lungs of mice at the 1- and 4-week time points. While CAN➙CTN transversions were again preferentially detected 1 week after urethane exposure (Fig. 2a, b, Supplementary Fig. 3a, b, and Supplementary Data 4, 5), indicating urethane mutagenesis occurred in this exon, oncogenic mutations were rarely recovered in either codon 12 or 13 (Fig. 2c). Interestingly, some G₁₂ and G₁₃ mutations were detected at a low frequency 4 weeks after urethane exposure (Fig. 2d). It is worth noting that oncogenic mutations at G₁₂ have been reported in urethane-induced tumors²¹, but are quite rare. This suggests that G₁₂ and G₁₃ mutations are induced by urethane exposure, but remain below the limit of detection of MDS unless a certain degree of clonal expansion occurs. Similarly, while a Q₆₁H (A₁₈₃>T) mutation was rarely detected 1 week after urethane exposure (Fig. 1f), it was more prevalent in later samples (Fig. 1d and Supplementary Data 2). Collectively, these findings argue that the mutational position tropism of urethane can be ascribed in large part to a mutational bias of this environmental carcinogen toward CAN➙CT/GN mutations.

**Fig. 2: MDS detects the position and substitution tropism of urethane.**

Isoform tropism

The other two Ras genes, Hras and Nras, encode the identical codon 61 (CAA). CAN➙CT/GN substitutions at this codon generate the identical oncogenic Q₆₁L/R mutations, which are well known to render Hras and Nras oncogenic^22,23. Despite this, oncogenic mutations in Hras or Nras are not recovered in urethane-induced lung tumors³. This suggests that either these loci are resistant in some manner to urethane mutagenesis or oncogenic mutations in these two genes are unable to initiate tumorigenesis. To differentiate between these two possibilities, we optimized the MDS assay to detect mutations in the non-transcribed strand of exon 2 in Hras (see Methods). We then applied this approach to genomic DNA isolated from the lungs of mice 1 and 4 weeks after exposure to urethane or PBS. We found a high prevalence of A>T followed by A>G mutations in exon 2 of Hras (Fig. 3a and Supplementary Data 6), with again CAN➙CTN transversions being the predominant mutation in the urethane cohort, including the oncogenic CA₁₈₂A➙CTA mutation in codon 61 (Fig. 3b). CAN➙CTN transversions in Hras were detected somewhat less often than in Kras 1 week (Fig. 3c), but similarly 4 weeks after urethane exposure (Fig. 3d). Unlike in the case of Kras, however, oncogenic mutations in Hras did not expand appreciably over time (Fig. 3d). Hras therefore appears to acquire oncogenic mutations at a detectable frequency, but such mutations do not support tumorigenesis. This suggests that the isoform tropism of urethane is a product of the Hras locus and not an inability to induce oncogenic mutations at this site.

Organ tropism

Pulmonary lesions are the primary tumors arising in mice after intraperitoneal injections of urethane². However, activating an oncogenic Kras allele in a broad spectrum of murine organs has been documented to be tumorigenic²⁴. This begs the question of why urethane fails to induce other types of tumors. We thus analyzed the mutation status by MDS of the non-transcribed strand of exon 2 of Kras from lung compared with the liver and pancreas from mice 1 and 4 weeks after exposure to urethane versus PBS. The liver was chosen as in rare cases tumors develop in this organ during urethane carcinogenesis^25,26. The pancreas was chosen as it is sensitive to tumorigenesis by oncogenic Kras mutations^27,28 but is not known to develop tumors after intraperitoneal injections of urethane². In comparison with the lung, significantly fewer CAN➙CTN transversions were recovered in the liver and pancreas 1 and 4 weeks after urethane exposure (Fig. 4a, b and Supplementary Data 7, 8). Again, unlike the situation in the lung, there was no overt expansion of Kras oncogenic mutations in the liver and pancreas over time, suggesting an absence of tumor growth (Fig. 4b). These findings argue that Kras acquires fewer mutations in these tissues after urethane exposure. To rule out the possibility that these tissues are less exposed to urethane, mice were injected with urethane or PBS and 2, 4, and 8 hours later the lungs, liver, and pancreas were removed and subjected to LC/MS/MS²⁹ to measure the levels of urethane and its active metabolite vinyl carbamate^2,30. Similar levels of both compounds were detected in the lungs and liver, but less in the pancreas over the three time points, with the terminal time point showing the highest concentration in the liver, followed by the lung, and then the pancreas (Supplementary Fig. 4a, b), similar to results from the lung and liver using radiolabeled urethane³¹. These findings argue that the organ tropism of urethane appears to arise from differences in mutagenesis between tissues, rather than differential carcinogen exposure.

Strand bias

Given the above differences in the mutation frequency between different tissues, we revisited the MDS sequencing of the Kras locus, finding a bias toward mutations in the non-transcribed strand in mice exposed to urethane. In more detail, MDS targeting the non-transcribed strand of Kras exon 2 revealed that CAN➙CTN, but not the complement NTG➙NAG transversions, were the predominant mutations in the lungs of mice 1 week after exposure to urethane (Fig. 5a). To independently validate this result, we performed MDS targeting the opposite (transcribed) strand of exon 2 of Kras from the lungs of mice 3 weeks after exposure to urethane or PBS (Supplementary Data 3). This revealed a bias toward NTG➙NAG over CAN➙CTN transversions in the transcribed strand (Fig. 5b). The same was true for exon 1 of Kras, namely a bias toward CAN➙CTN transversions in the non-transcribed strand compared with the transcribed strand, as determined from sequencing both strands by MDS (Supplementary Fig. 5a, b). Thus, based on sequencing both strands in two different exons of Kras in the lung, urethane mutagenesis exhibits a bias for the non-transcribed strand.

Mutational strand asymmetry has been observed for other mutational processes^32,33 and correlated with the transcriptional status of mutated genes³⁴. Kras mRNA levels determined by quantitative RT-PCR (RT-qPCR)³⁵ or RNA-seq³⁶ have been reported to be higher in the murine lung compared with the liver. In agreement, we validated the higher expression of Kras mRNA in lung compared with liver and pancreas by RT-qPCR (Fig. 5c). In addition, strand bias is not significant in the liver, consistent with a general lack of mutations detected in this organ after urethane exposure (Fig. 5d). Prompted by this, we examined the relationship between mutation frequency and gene expression using mutations detected in a previous published whole-exome sequencing of urethane-induced lung adenomas and adenocarcinomas³ and a published RNA-seq dataset generated from the adult mouse lung³⁶. Genes were partitioned into quartiles based on expression level and the number of CAN➙CTN transversions in non-transcribed or transcribed strand in each quartile determined. In agreement with the transcriptional strand bias revealed by MDS sequencing, CAN➙CTN transversions increased with gene expression on the non-transcribed strand but decreased on the transcribed strand (Fig. 5e). The same trends were observed when the RNA-seq dataset for adult mouse lung from the mouse ENCODE project³⁷ was analyzed (Supplementary Fig. 5c). Collectively, these findings point toward the organ tropism of urethane being related to the high transcription of Kras in the lung.

Discussion

Here we adapted MDS, an error-corrected, high-throughput sequencing approach originally developed for use in microbiology¹³, to now detect extremely rare mutations in the mammalian genome at a sensitivity of up to 5 × 10⁻⁷ (1 mutant per 2 × 10⁶ templates). While we developed this assay to study RAS mutation tropism, MDS could find value in other applications¹³, such as early detection³⁸. Nevertheless, by leveraging MDS to study the mutagenesis process at the earliest stage of tumorigenesis, we detected the initiating Q₆₁L/R mutations in Kras in the lungs of mice only days after exposure to urethane, capturing the very birth of cancer. We note that mutant allele-specific amplification^39,40 and droplet digital PCR⁴¹ have documented Kras mutations after carcinogen exposure. However, we chose to develop MDS for the mammalian settings as these assays are either not as quantitative and sensitive^39,42, or are designed to examine pre-selected mutations^41,43. Indeed, capitalizing on the ability of MDS to detect potentially any sequence variation in targeted regions of Ras genes at great sensitivity, we show at least three features underpinning the extreme mutational tropism of urethane—the mutational bias of this environmental carcinogen, transcription, and the gene locus.

With regards to the substitution and position bias of urethane, we demonstrate that the prevalence of Q₆₁L/R mutations arises in large part due to the known preference of urethane for A>T/G substitutions³, especially as we show here in the context of a 5ʹ C. This mutational bias, coupled with codon 61 containing a CAN trinucleotide that when the A is mutated to either T or G gives rise to an oncogenic L (CT₁₈₂A) or R (CG₁₈₂A) amino acid, favors the Kras^Q61L/R driver mutation characteristic of this carcinogen. Other oncogenic mutations at Q₆₁, G₁₂, or G₁₃ codons do not result from CA➙CT/G substitutions, and in agreement, were rarely detected following urethane exposure. The implication being that a mutagenic preference may influence the type of initiating mutations in cancer. Similarly in humans, a CCT➙CTC mutation characteristic of C>T transitions induced by UV encodes an activating P₂₉S mutation in RAC1 in sun-exposed melanoma⁴⁴.

While Q₆₁H, G₁₂, and G₁₃ oncogenic mutations in Kras, which are not favored by urethane mutagenesis, were rare or absent 1 week after urethane exposure, they were detected 4 weeks later. This implies that extremely rare mutations induced by urethane, provided they have a favorable oncogenic outcome, may initiate tumorigenesis (although we cannot formally rule out that these were pre-existing mutations unveiled by a cooperating mutation induced by urethane). In agreement, while the Q₆₁L mutation is more frequent than Q₆₁R in urethane-induced lung tumors of the A/J mouse strain, the reverse is true in the B6 strain⁵. Similarly, the mutation spectrum of urethane is also shifted in a variety of mutant Ras backgrounds^3,24,45,46. If the mutagenesis preference of urethane is independent of strain background, the prevalence of the Q₆₁R mutation suggest that this less common mutation is more conducive to tumor initiation in the B6 strain. As such, the most dominant mutation of a mutagen may not always dictate the initiating event, echoing reported discordances between the mutagenic signatures and the putative initiating mutation in certain human cancers^47,48,49.

Another fascinating feature of urethane mutagenesis revealed by MDS sequencing relates to isoform tropism. We found that codon 61 was readily mutated in Hras in lung tissue, yet the oncogenic Hras allele was not expanded appreciably over time. This suggests that either Hras^Q61L is not as oncogenic as Kras^Q61L or the encoded protein is expressed too low (or high) to be tumorigenic. In support of the first, RAS isoforms differ in their residency at different membranes⁵⁰ and the composition of proteins within the immediate vicinity differs between RAS isoforms^51,52, with proteins like PIP5K1A⁵², calmodulin⁵³, galectin-3⁵⁴, and so forth documented to specifically associate with KRAS. In support of the second, a Kras allele whereby the 3ʹ end was replaced with Hras exons to encode Hras protein was found mutated in urethane-induced tumors⁵⁵, indicating that under a Kras promoter Hras^Q61L is indeed oncogenic in the lung. Whether the inability of oncogenic mutations in Hras to promote lung tumorigenesis is because the protein is less oncogenic, expressed too low, too high, combinations thereof, or for other reasons^7,24,56,57 remains to be elucidated. Nevertheless, the finding that Hras is mutated yet such mutations are not recovered in lung tumors³ after urethane exposure is in itself an important finding, and perhaps related, of the three RAS genes, HRAS is mutated the least often in human cancers^6,7,58.

With regards to organ tropism, a very different mechanism appears to be at play. In this case, we found that Kras is rarely mutated in the liver and pancreas, despite the presence of the carcinogen. While a number of factors could contribute to this variation in mutagenesis^59,60,61, one notable difference is that Kras mRNA levels are higher in the lung compared with these other tissues, suggestive of increased transcription. In fact, the lung was found to have the second highest levels of Kras mRNA of 15 adult murine tissues analyzed, second only to the brain³⁵. Kras expression in the mouse lung also correlates with strain susceptibility to urethane carcinogenesis^62,63. Related, we discovered that the non-transcribed strand of Kras is preferentially mutated, which for other mutagens has been linked to transcription-coupled repair of the transcribed strand⁶⁴ or transcription-coupled damage of the displaced, non-transcribed strand³⁴. Indeed, we found a global correlation between mRNA levels and the mutation frequency of urethane. This is not to say that there is a universal concordance between high gene transcription and an elevated mutation frequency of the non-transcribed strand. Indeed, high transcription has been associated with a lower mutation frequency in chromatin-dense genomic regions in cutaneous squamous cell carcinomas⁶⁵. Thus, the type of cancer, mutational process, specific genes, and so forth may influence the bias of a mutagenic process. In the case of urethane, however, we suggest that the tissue tropism is related to the high transcription of Kras in the lung, increasing the susceptibility of this gene to urethane mutagenesis.

In humans, there are also very distinct patterns to RAS mutations at the level of the organ (e.g., RAS is commonly mutated in pancreatic but rarely in breast cancer), isoform (e.g., KRAS is mutated in lung cancer while NRAS is mutated in melanoma), position (e.g., G₁₂ is mutated in CMML while Q₆₁ is mutated in thyroid carcinoma), and substitution (e.g., G₁₂V is the primary mutation in bladder carcinoma while it is G₁₂S in mouth carcinoma). There is no definitive mechanism to explain this phenomenon, although the pattern itself has been widely reported for decades^{6,7,24,58,66,67,68}. In this regard, the extreme specificity of urethane carcinogenesis for Kras^Q61L/R-mutant pulmonary tumors may inform the basic principles of the RAS mutation patterns observed in these clinical samples. Admittedly, urethane is not a major environmental carcinogen in humans compared with, for example, tobacco smoke. Kras^Q61L/R mutations are also rare in human lung cancers²⁴. With these two provisos, we speculate that the RAS mutation tropism of human cancers may similarly be a product of mutagenesis selectivity factors, for example the specificity of the mutagenic process or susceptibility of a specific locus to mutations, and selection factors, for example differences in the oncogenic activity of one isoform over another. Moreover, it is entirely possible, if not likely, that different combinations of these or even other factors such as cooperating mutations, as elegantly demonstrated in MNU carcinogenesis³, cell type⁶⁹, signaling intensity⁴⁵, and so forth²⁴ underlie the RAS mutation tropism human cancers. As such, each cancer initiating event may be molded by a unique set of factors, each with varying influence.

Methods

Cell culture

Mouse embryonic fiborblasts (MEFs) derived from E13.5 mouse embryos were stably infected with an ecotropic retrovirus derived from pBabeHygro⁷⁰ encoding the early region of SV40⁷¹ and selected with 100 μg.ml⁻¹ hygromycin to establish immortalized cultures using standard procedures and then cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.

Construction of Kras-mutant plasmids

A region upstream of Kras start codon was amplified from murine genomic DNA (termed PCR1). PCR reactions were comprised of 100 ng of genomic DNA, 2.5 μl of 10 μM forward (5ʹ-AATTGCGGCCGCCCAGGGGGTATAGCGTACTATGCAGAAT-3ʹ) and reverse (5ʹ-CATTTTCAGCAGGCCTTACAAT-3ʹ) primers, 4 μl of 2.5 mM dNTP, 10 μl of 5X buffer (NEB), and 0.5 μl Q5® Hot Start High-Fidelity DNA Polymerase (NEB) in a total volume of 50 μl. PCR cycles were as follows: one cycle at 98 °C for 30 s, 28 cycles at 98 °C for 8 s, 64 °C for 15 s, 72 °C for 10 s, and one cycle at 72 °C for 2 min. PCR products were gel purified using QIAquick Gel Extraction Kit following the manufacturer’s protocol (Qiagen).

Mutations in Kras cDNA were generated through error-prone PCR (termed PCR2). PCR reactions were comprised of 15 nmol of plasmid containing Kras cDNA, 2 μl of 10 μM forward (5ʹ-ATTGTAAGGCCTGCTGAAAATGACTGAGTATAAACTTGTGGT-3ʹ) and reverse (5ʹ-CAGGGTCGACTCACATAACTGTACACCTTGTC-3ʹ) primers, 2 μl of 2.5 mM dNTP, 1.25 μl of 50 mM MgCl₂, 2.5 μl of 10x buffer (Invitrogen), 5 μl of 2.5 mM MnCl₂, and 0.2 μl of Platinum Taq DNA polymerase (Invitrogen) in a total volume of 25 μl. PCR cycles were as follows: one cycle at 94 °C for 1 min, 18 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 3 min, and one cycle at 72 °C for 3 min. PCR products were gel purified as described above.

Products from PCR1 and PCR2 were fused through overlap PCR (termed PCR3). Twenty nanograms product from PCR1 and 40 ng product from PCR2 were mixed with 4 μl of 2.5 mM dNTP, 10 μl of 5X buffer (NEB), and 0.5 μl Q5® Hot Start High-Fidelity DNA Polymerase (NEB) in a total volume of 50 μl reaction. PCR cycles were 98 °C for 30 s and 10 cycles at 98 °C for 8 s, 63 °C for 15 s, and 72 °C for 15 s. 2.5 μl of forward primer from PCR1 and 2.5 μl of reverse primer from PCR2 were then added and the reaction was continued in the following conditions: 98 °C for 30 s, 25 cycles at 98 °C for 8 s, 72 °C for 40 s, and one cycle at 72 °C for 2 min. PCR products were gel purified as described above.

Plasmid backbone was amplified from the pUC19⁷² (Addgene 50005) plasmid (termed PCR4). PCR reactions were comprised of 1 ng of pUC19 DNA, 2.5 μl of 10 μM forward (5ʹ-AATTGTCGACTTAGACGTCAGGTGGCAC-3ʹ) and reverse (5ʹ-TTAAGCGGCCGCGTTTGCGTATTGGGCGCT-3ʹ) primers, 4 μl of 2.5 mM dNTP, 10 μl of 5X buffer (NEB), and 0.5 μl Q5® Hot Start High-Fidelity DNA Polymerase (NEB) in a total volume of 50 μl. PCR cycles were as follows: one cycle at 98 °C for 30 s, 28 cycles at 98 °C for 8 s, 65 °C for 15 s, 72 °C for 1 min, and one cycle at 72 °C for 2 min. PCR products were gel purified as described above.

Products from PCR3 and PCR4 were digested with SalI and NotI according the manufacture’s protocol (NEB). Digested products were column purified using QIAquick PCR Purification Kit following the manufacturer’s protocol (Qiagen), ligated, and transformed using standard methodologies. DNA was isolated from individual clones by NucleoSpin® Plasmid miniprep kit (MACHEREY-NAGEL) and validated by Sanger sequencing. Ten clones with different sets of co-occurring mutations in Kras exon 1 and/or 2 were selected to be spiked into wild-type mouse genomic DNA at different ratios to test the detection limit of maximum-depth sequencing (see below).

Urethane treatment

Six- to eight-week-old male and female A/J mice (JAX Stock #000646) were intraperitoneally injected daily for 3 days with either urethane (Sigma U2500) dissolved in PBS (1 g.kg⁻¹) or the vehicle PBS alone. Mice were humanely euthanized 1, 2, 3, or 4 weeks after the last injection and the lung, liver, and pancreas collected for the extraction of genomic DNA. All mouse care and experiments were performed in accordance with protocols approved by the IACUC of Duke University.

Pharmacokinetic analysis

Six- to eight-week-old male and female A/J mice (JAX Stock #000646) were intraperitoneally injected with one dose of urethane dissolved in PBS (1 g.kg⁻¹). Mice were humanely euthanized 2, 4, and 8 h later after which plasma, lungs, pancreas, and livers were harvested and snap frozen. Liquid chromatography (LC) tandem-mass spectrometry (MS/MS) was used to measure urethane (ethyl carbamate, EC) (Sigma U2500) and vinyl carbamate (VC) (Santa Cruz Biotechnology sc-213157) concentrations in plasma and tissues. The LC-MS/MS system consisted of Shimadzu 20A series LC and Applied Biosystems/SCIEX API 4000 QTrap MS/MS instrument. LC columns: Phenomenex C₁₈ 3 × 4 mm guard column (#AJ0-4287) and Agilent ZORBAX Eclipse Plus C₁₈ 150 × 4.6 mm 1.8-μm analytical column (#959994-902). Mobile phase A: 0.1% formic acid, 10 μM sodium acetate, and 2% acetonitrile; mobile phase B: 100% methanol. Elution gradient: isocratic flow 30% A. Flow rate: 0.8 ml.min⁻¹. The run time was 10 min. Calibration samples were prepared by adding pure standards of EC or VC to corresponding matrix (plasma or tissue homogenate) in appropriate concentration range. The calibration samples were analyzed alongside study samples as a single analytical batch on the day of analysis.

In 2 ml screw cap vial, 20 μl (EC) or 50 μl (VC) of plasma or tissue homogenate (1 part tissue and 2 parts water) diluted with water 1/100 (EC) or undiluted (VC), 10 μl of 2 μg.ml⁻¹ MC-d5 in water (internal standard) (Toronto Research Chemicals), and 60 μl (EC) or 100 μl (VC) of 20 mM xanthydrol (Sigma) in glacial HAc were added and incubated at room temperature for 30 min. Hundred microliters of water and 500 μl of chloroform were then added and the mixture was vigorously agitated (speed 4, 40 s; Fast-Prep FP120, Thermo Savant). After centrifugation at 16,000 × g for 5 min at room temperature, 200 μl (EC) or 400 μl (VC) of chloroform (lower) layer was subjected to a gentle stream of nitrogen for 30 min, dry residue reconstituted with 50 μl (EC) or 100 μl (VC) 50% A/50% B, centrifuged at 16,000 × g for 5 min at 4 °C, after which 5 μl (EC) or 10 μl (VC) was injected into LC-MS/MS system. The mass spectrometer was operated in positive mode with the following MRM transitions (m/z): 292/180.8 [EC-1st], 292/151.3 [EC-2nd], 297/181.8 [EC-d5-1st], 297/151.7 [EC-d5-2nd] for EC and 290/180.5 [VC-1st], 290/151.2 [VC-2nd], 297/181.8 [EC-d5-1st], 297/151.7 [EC-d5-2nd] for VC.

Isolation of genomic DNA

MEF cells were resuspended in lysis buffer (100 mM NaCl, 10 mM Tris pH 7.6, 25 mM EDTA pH 8.0, and 0.5% SDS in H₂O, supplemented with 20 μg.ml⁻¹ RNase A (Sigma)). Lung, pancreas, and liver (right lobe) from A/J mice (JAX Stock #000646) were cut into fine pieces and similarly resuspended in lysis buffer. Samples were incubated at 37 °C for 1 hr. Two microliters of 800 U.ml⁻¹ proteinase K (NEB) was then added to each sample, the samples were vortexed, and then incubated at 55 °C overnight. Genomic DNA was isolated by phenol/chloroform extraction followed by ethanol precipitation using standard procedures and quantified using Qubit fluorometer.

Maximum-depth sequencing (MDS)

The MDS assay¹³ was adapted for mammalian Ras genes as follows. Twenty to fifty micrograms of genomic DNA was incubated with StuI (NEB) for analysis of the transcribed strand of Kras exon 1, EcoRV (NEB) and EcoRI (NEB) for analysis of the non-transcribed strand of Kras exon 1, XmnI (NEB) for analysis of the non-transcribed strand of Kras exon 2, and PleI (NEB) for analysis of the transcribed strand of Kras exon 2, or HphI (NEB) for the analysis of the non-transcribed strand of Hras exon 2. Reaction conditions were 5 units of the indicated restriction enzyme and per 1 μg DNA per 20 μl reaction (e.g., 20 μg genomic DNA, 5 μl enzyme (20 units.μl⁻¹), and 40 μl 10X buffer in 400-μl reaction). Digested genomic DNA was column purified using QIAquick PCR Purification Kit following the manufacturer’s protocol (Qiagen) and resuspended in ddH₂O (35 μl H₂O per 10 μg DNA). The barcode and adaptor were added to the target DNA by incubating purified DNA with the appropriate barcode primer (see below) for one cycle of PCR. PCR reactions were comprised of 10 μg DNA, 2.5 μl of 10 μM barcode primer, 4 μl of 2.5 mM dNTP, 10 μl of 5X buffer (NEB), and 0.5 μl Q5® Hot Start High-Fidelity DNA Polymerase (NEB) in a total volume of 50 μl. The number of PCR reactions was scaled according to the amount of DNA. PCR conditions were 98 °C for 1 min, barcode primer annealing temperate (see below) for 15 s, and 72 °C for 1 min. One microliter of 20,000 U.ml⁻¹ exonuclease I (NEB) and 5 μl of 10X exonuclease I buffer (NEB) was then added to each 50 μl reaction to remove unused barcoded primers and incubated at 37 °C for 1 h and then 80 °C for 20 min. Processed DNA were column purified using QIAquick PCR Purification Kit as above and resuspended in ddH₂O (35 μl H₂O per column). The concentration of purified product was measured with SimpliNano spectrophotometer (GE Healthcare Life Sciences). Samples were linear amplified with forward adaptor primer (see below). PCR reactions were comprised of 1.5 μg DNA, 2.5 μl of 10 μM forward-adaptor primer, 4 μl of 2.5 mM dNTP, 10 μl of 5X buffer (NEB), and 0.5 μl Q5® Hot Start High-Fidelity DNA Polymerase (NEB) in a total volume of 50 μl. The number of PCR reactions was scaled according to the amount of DNA. PCR conditions were as follows: 12 cycles of 98 °C for 15 s, 70 °C for 15 s, 72 °C for 8 s. 2.5 μl of 10 μM exon-specific reverse primer (see below) and 2.5 μl of 10 μM reverse-adaptor primer (see below) were then added to each 50 μl reaction. The mixtures were then subjected to 20 cycles of exponential amplification. PCR conditions were as follows: 4 cycles of 98 °C for 15 s, exon-specific reverse primer annealing temperature (see below) for 15 s, 72 °C for 8 s, 16 cycles of 98 °C for 15 s, 70 °C for 15 s, and 72 °C for 8 s. The final library was size selected and purified with Ampure XP beads according to the manufacturer’s protocol (Beckman Coulter). Sequencing was performed using HiSeq 2500 100 bp PE rapid run, HiSeq 4000 150 bp PE or NovaSeq 6000 S Prime 150 bp PE at Duke Center for Genomic and Computational Biology. For the optimization of barcode recovery, the same amount of genomic DNA was processed in parallel by MDS assay targeting Kras exon 1 transcribed strand and the PCR products were pooled together at different concentrations in one library to obtain different sequencing depths.

Primers for maximum-depth sequencing

Barcode primer: [Forward adaptor][Index][Barcode][Primer]

Where

[Forward adpator] = 5ʹ-TACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3ʹ

[Index] = variable length of known sequences from 0 to 7 nucleotides (Supplementary Data 1)

[Barcode] = NNNNNNNNNNNNNN

Kras exon 1 StuI [Primer] = 5ʹ-CCTGCTGAAAATGACTGAG-3ʹ (annealing temperature: 60 °C)

Kras exon 1 EcoRV [Primer] = 5ʹ-ATCTTTTTCAAAGCGGCTGGCT-3ʹ (annealing temperature: 68 °C)

Kras exon 2 XmnI [Primer] = 5ʹ-TCTTCAAATGATTTAGTATTATTTATGGC-3ʹ (annealing temperature: 59 °C)

Kras exon 2 PleI [Primer] = 5ʹ-TCAGGACTCCTACAGGAAAC-3ʹ (annealing temperature: 63 °C)

Hras exon 2 HphI [Primer] = 5ʹ-TAGGTGGCTCACCTGTACTG-3ʹ (annealing temperature: 66 °C)

Forward-adaptor primer: 5ʹ-AATGATACGGCGACCACCGAGAT-3ʹ (annealing temperature: 70 °C)

Exon-specific reverse primer: [Reverse adaptor][Index][Primer]

Where

[Reverse adaptor] = 5ʹ-AAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-3ʹ

(for barcode recovery optimization and Kras exon 2 mutant plasmid spike-in experiment) or

5ʹ-CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3ʹ

(for all the other experiments)

[Index] = variable length of known sequences from 0 to 7 nucleotides (Supplementary Data 1)

Kras exon 1 StuI [Primer] = 5ʹ-CTCTATCGTAGGGTCATACTCAT-3ʹ (annealing temperature: 62 °C)

Kras exon 1 EcoRV [Primer] = 5ʹ-TATTATTTTTATTGTAAGGCCTGCTGA-3ʹ (annealing temperature: 62 °C)

Kras exon 2 XmnI [Primer] = 5ʹ-GACTCCTACAGGAAACAAGT-3ʹ (annealing temperature: 61 °C)

Kras exon 2 PleI [Primer] = 5ʹ-CTTTCTTATTCAACTTAAACCCAC-3ʹ (annealing temperature: 59 °C)

Hras exon 2 HphI [Primer] = 5ʹ-CTAAGCCGTGTTGTTTTGCAG-3ʹ (annealing temperature: 65 °C)

Reverse-adaptor primer: 5ʹ-CAAGCAGAAGACGGCATACGAGA-3ʹ (annealing temperature: 70 °C)

All primers were synthesized by Integrated DNA Technologies (IDT).

Data analysis

All sequencing data were analyzed through the Galaxy web platform⁷³. Specifically, raw data were uploaded to usegalaxy.org or Galaxy Cloudman. For analysis of Kras exon 1 transcribed strand in mouse lung tissue, only read 1 was used. For all the other experiments, read 1 and read 2 were joined via PEAR pair-end read merger⁷⁴. The reads were then filtered by quality by requiring 90% of bases in the sequence to have a quality core ≥20. Filtered reads were split into different files based on assigned sample indexes and variation in sequence lengths using the tool Barcode Splitter and the tool Filter Sequences by Length.

For the experiment optimizing barcode recovery, the reads were trimmed down to the barcode and grouped into families by barcode. The number of families containing 1 read and ≥2 reads was then counted, respectively.

For the mutant plasmid spike-in experiments, the reads were trimmed down to the barcode and the bases containing engineered mutations. Trimmed reads were grouped by barcode into different families. The frequency of mutants present was calculated by dividing the counts of families containing engineered co-occurring mutations by the total number of families. The frequency of mutants detected was calculated by dividing the counts of families containing ≥2 reads and have ≥90% reads sharing the same engineered mutation at one specified position by the total number of families.

For the experiments examining carcinogen-induced mutations in Kras exon 1 or 2, the reads were trimmed down to the barcode and the target exon. Trimmed reads were grouped by barcode. Barcode families containing ≥3 reads and a unique consensus sequence were selected. To ensure sufficient barcode recovery for the purpose of sensitivity and accuracy, samples with <1.5 × 10⁵ barcode families recovered were excluded from downstream analysis. Sequences from selected barcode families were compared against annotated reference mutant sequences containing all possible single-nucleotide substitutions in the exon of interest and the mutation in the reference mutant sequence was assigned to the matched barcode family. The frequency of the corresponding mutation was calculated by dividing the counts of the families containing the mutation by the total number of families.

C>T and G>T substitutions have high background in PBS-treated mouse and have been previously identified as artifacts caused by deamination of cytosine or methyl-cytosine or oxidation of guanine arising during in library preparation^11,75, or mis-incorporated nucleotides in vivo not yet repaired¹³. Consistent with this, we detect high C>T or G>T substitutions but not the complementary G>A or C>A substitutions from the strand processed by MDS (Supplementary Data 2–8). To circumvent this background, the frequency of C>T or G>T substitutions was estimated from the strand with the reverse-complementary G>A or C>A substitutions when necessary. Specifically, frequency of G_12/13C and G_12/13V mutations in Kras exon 1 (G>T substitution on the non-transcribed strand) were estimated from the MDS targeting the transcribed strand while frequency of G_12/13S and G_12/13D mutations in Kras exon 1 (C>T substitutions on the transcribed strand) were estimated from MDS targeting the non-transcribed strand.

Droplet digital PCR (ddPCR)

ddPCR was performed using the QX200 AutoDG Droplet Digital PCR System (Bio-Rad) following the manufacturer’s protocol in a 22 µl ddPCR reaction containing 11 µl of 2x ddPCR SuperMix for probes (no dUTP) (Bio-Rad), 66 ng template DNA, 450 nM forward and reverse primers, and 250 nM FAM- and HEX-labeled probes. The primer and probe oligonucleotides were synthesized (IDT) based on sequences previously described⁷⁶ with minor modifications. The sequences for the primers are Kras_Q61_For: 5ʹ-ATGGAGAAACCTGTCTCTTGG-3ʹ and Kras_Q61_Rev: 5ʹ-CTCATGTACTGGTCCCTCATT-3ʹ. The sequences for the probes are Kras_Q61L_MUT_FAM: 5ʹ-/56-FAM/CAGGT+C+T+AGA+GGAG/3IABkFQ/-3ʹ and Kras_Q61L_WT_HEX: 5ʹ-/5HEX/CAGGT+C+A+AGA+GGAG/3IABkFQ/-3ʹ where “+” denotes the following base is a locked nucleic acid. Following droplet generation on the AutoDG, the plate was sealed with pierceable foil heat seal (Bio-Rad) and PCR performed on a C1000 Touch™ thermal cycler (Bio-Rad). Thermal cycling conditions were as follows: once cycle at 95 °C for 10 min, 40 cycles at 94 °C for 30 s and 60 °C for 60 s, once cycle at 98 °C for 10 min, and 4 °C until the sample was removed. Every ddPCR run included no template control, wild type control with DNA from PBS-treated mice, and mutation-positive control. To achieve detection sensitivity of 1 in 10,000, each sample was assayed in at least two wells. Plates were read on a QX200 droplet reader (Bio-Rad) and analyzed with QuantaSoft™ Analysis Pro software (version 1.0.596) (Bio-Rad) to assess the number of droplets positive for mutant DNA, wild-type DNA, both, or neither. The mutant allele fraction⁴³ was estimated as follows: The concentration of mutant DNA (copies of mutant DNA per droplet) was estimated from the Poisson distribution using the formula number of mutant copies per droplet Mmu = −ln (1− (nmu/n)), where nmu = number of droplets positive for mutant FAM probe and n = total number of droplets. The DNA concentration in the reaction was estimated using the formula MDNAconc = −ln (1 − (nDNAcon/n)), where nDNAconc = number of droplets positive for mutant FAM probe and/or wild-type HEX probe and n = total number of droplets. The mutant allele fraction = Mmu/MDNAconc.

RNA isolation and quantitative PCR

RNA was extracted from the lung, liver and pancreas of 6-week-old A/J mice using TRIzol (Thermo Fisher Scientific) and converted to cDNA using iScript™ cDNA Synthesis Kit (Bio-Rad) following the manufacturer’s instructions. Quantitative PCR reactions were performed using iTaq Universal SYBR Green Supermix (Bio-Rad) and CFX384 touch real-time PCR detection system (Bio-Rad) using the forward (5ʹ-CCAGCGTCGTGATTAGCGA-3ʹ) and reverse (5ʹ-CCAGCAGGTCAGCAAAGAAC-3ʹ) primers (IDT) to detect the control Hprt mRNA and the forward (5ʹ-GCAAGAGCGCCTTGACGATA-3ʹ) and reverse (5ʹ-CATGTACTGGTCCCTCATTGCAC-3ʹ) primers (IDT) to detect Kras mRNA. Gene expression values were calculated using the comparative Ct (−∆∆Ct) method⁷⁷, using Hprt housekeeping gene as internal control.

Whole-exome analysis of mutation frequency versus gene expression

Mutation counts were obtained from published datasets³ [https://www.nature.com/articles/nature13898#Sec19]. Single-nucleotide variations (SNVs) identified by the whole-exome sequencing of urethane-induced adenomas and adenocarcinomas were examined. The expression level of the genes containing these SNVs were determined from published datasets³⁶ [https://www.nature.com/articles/s41598-017-04520-z#Sec18]. FPKM values of genes expressed in the lung of 6-weeks-old C57BL/6JJcl mice were used. The second set of gene expression data³⁷ were obtained from mouse ENCODE project [http://chromosome.sdsc.edu/mouse/download.html]. FPKM values of genes expressed in the lung of 8-week-old male C57Bl/6 mice were used. To bin the genes into different expression groups, the genes were sorted by the mean FPKM value across biological replicates and split into quartiles. The sum of CAN➙CTN transversions in the non-transcribed or transcribed strand for the genes in each quartile was calculated and the mean ± SEM of all tumors was plotted.

Generation of heatmaps

All heatmaps were generated using Morpheus (https://software.broadinstitute.org/morpheus). All mutation frequencies used in heatmap were corrected by the addition of the detection limit at a barcode recovery of 1.5 × 10⁵ (~6.67 × 10⁻⁶). For the heatmap showing the mutation frequency per nucleotide (Fig. 1b), the sum of the corrected mutation frequencies for all substitutions at an individual nucleotide was obtained, then the fold change of each urethane-treated sample versus the average of PBS-treated samples was calculated and log₁₀ transformed for plotting. For the heatmaps showing the mutation frequency of each type of substitution (Figs. 1c, 2a, and 3a), the sum of the corrected mutation frequencies for each type of substitutions was obtained, then the fold change of each urethane-treated sample versus the average of PBS-treated samples was calculated and log₁₀ transformed for plotting. For the heatmaps showing the mutation frequency of A>T transversions (Figs. 1d, 2b, and 3b; Supplementary Figs. 2a and 3a), the corrected mutation frequency for each A>T transversion was log₁₀ transformed and plotted.

Statistics

The number of independent experiments and the statistical analysis used are indicated in the legends of each figure. Data are represented as mean ± SEM. p values were determined by Holm-Sidak multiple comparisons test following one-way or two-way ANOVA, non-parametric Dunn’s multiple comparison test following Kruskal–Wallis test, or two-tailed non-parametric Mann–Whitney U test. p < 0.05 was considered significant. Different levels of significance are indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 and ns: not significant. Holm-Sidak multiple comparisons test following ANOVA and non-parametric Dunn’s multiple comparison test following Kruskal–Wallis test were executed using GraphPad Prism 6. Two-tailed non-parametric Mann–Whitney U test was executed using excel supplemented with Real Statistics Resource Pack (www.real-statistics.com).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All raw Illumina® sequencing data has been deposited to NCBI Sequence Read Archive (SRA) under accession number PRJNA561927. The remaining data can be found within the Article, Supplementary Information or available from the authors upon reasonable request.

References

You, M., Candrian, U., Maronpot, R. R., Stoner, G. D. & Anderson, M. W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc. Natl Acad. Sci. USA 86, 3070–3074 (1989).
Article ADS CAS PubMed PubMed Central Google Scholar
Forkert, P. G. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab. Rev. 42, 355–378 (2010).
Article CAS PubMed Google Scholar
Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).
Article ADS CAS PubMed Google Scholar
Nuzum, E. O., Malkinson, A. M. & Beer, D. G. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol. Carcinog. 3, 287–295 (1990).
Article CAS PubMed Google Scholar
Dwyer-Nield, L. D. et al. Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains. Int. J. Cancer 126, 125–132 (2010).
Article CAS PubMed PubMed Central Google Scholar
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Disco. 13, 828–851 (2014).
Article CAS Google Scholar
Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012).
Article CAS PubMed PubMed Central Google Scholar
Hernandez, L. G. & Forkert, P. G. In vivo mutagenicity of vinyl carbamate and ethyl carbamate in lung and small intestine of F1 (Big Blue x A/J) transgenic mice. Int. J. Cancer 120, 1426–1433 (2007).
Article CAS PubMed Google Scholar
Fox, E. J., Reid-Bayliss, K. S., Emond, M. J. & Loeb, L. A. Accuracy of next generation sequencing platforms. Gener. Seq. Appl. 1, 1000106 (2014).
Google Scholar
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535 (2011).
Article ADS PubMed PubMed Central Google Scholar
Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Lou, D. I. et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc. Natl Acad. Sci. USA 110, 19872–19877 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Jee, J. et al. Rates and mechanisms of bacterial mutagenesis from maximum-depth sequencing. Nature 534, 693–696 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453–1462 (1997).
Article CAS PubMed Google Scholar
Waterston, R. H. et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562 (2002).
Article ADS CAS PubMed Google Scholar
Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
Article CAS PubMed PubMed Central Google Scholar
Fernando, R. C., Nair, J., Barbin, A., Miller, J. A. & Bartsch, H. Detection of 1,N ⁶-ethenodeoxyadenosine and 3,N ⁴-ethenodeoxycytidine by immunoaffinity/³²P-postlabelling in liver and lung DNA of mice treated with ethyl carbamate (urethane) or its metabolites. Carcinogenesis 17, 1711–1718 (1996).
Article CAS PubMed Google Scholar
Forkert, P. G. et al. Oxidation of vinyl carbamate and formation of 1,N ⁶-ethenodeoxyadenosine in murine lung. Drug Metab. Dispos. 35, 713–720 (2007).
Article CAS PubMed Google Scholar
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
Article CAS PubMed Google Scholar
Winters, I. P. et al. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat. Commun. 8, 2053 (2017).
Article ADS PubMed PubMed Central CAS Google Scholar
Borrego, A. et al. Germline control of somatic Kras mutations in mouse lung tumors. Mol. Carcinog. 57, 745–751 (2018).
Article CAS PubMed Google Scholar
Burd, C. E. et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Disco. 4, 1418–1429 (2014).
Article CAS Google Scholar
Kiessling, M. K. et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget 6, 42183–42196 (2015).
Article PubMed PubMed Central Google Scholar
Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767–777 (2018).
Article CAS PubMed Google Scholar
Dragani, T. A., Manenti, G. & Della Porta, G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res. 51, 6299–6303 (1991).
CAS PubMed Google Scholar
Heston, W. E., Vlahakis, G. & Deringer, M. K. High incidence of spontaneous hepatomas and the increase of this incidence with urethan in C3H, C3Hf, and C3He male mice. J. Natl Cancer Inst. 24, 425–435 (1960).
Article CAS PubMed Google Scholar
Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302 (2007).
Article CAS PubMed Google Scholar
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).
Article CAS PubMed Google Scholar
Grebe, S. K. & Singh, R. J. LC-MS/MS in the clinical laboratory—Where to from here? Clin. Biochem Rev. 32, 5–31 (2011).
PubMed PubMed Central Google Scholar
Guengerich, F. P. & Kim, D. H. Enzymatic oxidation of ethyl carbamate to vinyl carbamate and its role as an intermediate in the formation of 1,N ⁶-ethenoadenosine. Chem. Res. Toxicol. 4, 413–421 (1991).
Article CAS PubMed Google Scholar
Nomeir, A. A., Ioannou, Y. M., Sanders, J. M. & Matthews, H. B. Comparative metabolism and disposition of ethyl carbamate (urethane) in male Fischer 344 rats and male B6C3F1 mice. Toxicol. Appl. Pharm. 97, 203–215 (1989).
Article CAS Google Scholar
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Article CAS PubMed PubMed Central Google Scholar
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836 (2019).
Article CAS PubMed PubMed Central Google Scholar
Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538–549 (2016).
Article CAS PubMed PubMed Central Google Scholar
Newlaczyl, A. U., Coulson, J. M. & Prior, I. A. Quantification of spatiotemporal patterns of Ras isoform expression during development. Sci. Rep. 7, 41297 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Li, B. et al. A comprehensive mouse transcriptomic bodymap across 17 tissues by RNA-seq. Sci. Rep. 7, 4200 (2017).
Article ADS PubMed PubMed Central CAS Google Scholar
Shen, Y. et al. A map of the cis-regulatory sequences in the mouse genome. Nature 488, 116–120 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. 9, eaan2415 (2017).
Article PubMed PubMed Central CAS Google Scholar
Ichikawa, T. et al. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett. 107, 165–170 (1996).
Article CAS PubMed Google Scholar
Yano, T., Yuasa, M., Murakami, A., Ichikawa, T. & Hagiwara, K. The detection of chemically initiated cells having the mutation of K-ras gene at an early stage of lung carcinogenesis in mice. Anal. Biochem. 244, 187–189 (1997).
Article CAS PubMed Google Scholar
Spella, M. et al. Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. Elife 8, e45571 (2019).
Article PubMed PubMed Central Google Scholar
van Mansfeld, A. D. & Bos, J. L. PCR-based approaches for detection of mutated ras genes. PCR Methods Appl. 1, 211–216 (1992).
Article PubMed Google Scholar
Pender, A. et al. Efficient genotyping of KRAS mutant non-small cell lung cancer using a multiplexed droplet digital PCR approach. PLoS ONE 10, e0139074 (2015).
Article PubMed PubMed Central CAS Google Scholar
Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006–1014 (2012).
Article CAS PubMed PubMed Central Google Scholar
Pershing, N. L. et al. Rare codons capacitate Kras-driven de novo tumorigenesis. J. Clin. Invest. 125, 222–233 (2015).
Article PubMed Google Scholar
Huang, L., Carney, J., Cardona, D. M. & Counter, C. M. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nat. Commun. 5, 5410 (2014).
Article ADS CAS PubMed Google Scholar
Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Bockler, B. & Graham, T. A. The effects of mutational processes and selection on driver mutations across cancer types. Nat. Commun. 9, 1857 (2018).
Article ADS PubMed PubMed Central CAS Google Scholar
Buisson, R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, eaaw2872 (2019).
Article ADS CAS PubMed PubMed Central Google Scholar
Dietlein, F. et al. Identification of cancer driver genes based on nucleotide context. Nat. Genet. 52, 208–218 (2020).
Article CAS PubMed PubMed Central Google Scholar
Hancock, J. F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–384 (2003).
Article CAS PubMed Google Scholar
Kovalski, J. R. et al. The functional proximal proteome of oncogenic Ras includes mTORC2. Mol. Cell 73, 830–44 e12 (2019).
Article CAS PubMed PubMed Central Google Scholar
Adhikari, H. & Counter, C. M. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat. Commun. 9, 3646 (2018).
Article ADS PubMed PubMed Central CAS Google Scholar
Villalonga, P. et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell Biol. 21, 7345–7354 (2001).
Article CAS PubMed PubMed Central Google Scholar
Elad-Sfadia, G., Haklai, R., Balan, E. & Kloog, Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279, 34922–34930 (2004).
Article CAS PubMed Google Scholar
To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40, 1240–1244 (2008).
Article CAS PubMed PubMed Central Google Scholar
McCreery, M. Q. & Balmain, A. Chemical carcinogenesis models of cancer: back to the future. Annu Rev. Cancer Biol. 1, 295–312 (2017).
Article Google Scholar
Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).
Article CAS PubMed PubMed Central Google Scholar
Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging ras back in the ring. Cancer Cell 25, 272–281 (2014).
Article CAS PubMed Google Scholar
Adar, S., Hu, J., Lieb, J. D. & Sancar, A. Genome-wide kinetics of DNA excision repair in relation to chromatin state and mutagenesis. Proc. Natl Acad. Sci. USA 113, E2124–E2133 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Hoffler, U. & Ghanayem, B. I. Increased bioaccumulation of urethane in CYP2E1−/− versus CYP2E1+/+ mice. Drug Metab. Dispos. 33, 1144–1150 (2005).
Article CAS PubMed Google Scholar
Supek, F. & Lehner, B. Clustered mutation signatures reveal that error-prone DNA repair targets mutations to active genes. Cell 170, 534–547 (2017).
Article CAS PubMed Google Scholar
To, M. D. et al. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat. Genet. 38, 926–930 (2006).
Article CAS PubMed PubMed Central Google Scholar
Dassano, A. et al. Mouse pulmonary adenoma susceptibility 1 locus is an expression QTL modulating Kras-4A. PLoS Genet. 10, e1004307 (2014).
Article PubMed PubMed Central CAS Google Scholar
Hanawalt, P. C. & Spivak, G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9, 958–970 (2008).
Article CAS PubMed Google Scholar
Zheng, C. L. et al. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep. 9, 1228–1234 (2014).
Article CAS PubMed PubMed Central Google Scholar
Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
Article CAS PubMed PubMed Central Google Scholar
Haigis, K. M. KRAS alleles: the devil is in the detail. Trends Cancer 3, 686–697 (2017).
Article CAS PubMed PubMed Central Google Scholar
Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
CAS PubMed Google Scholar
Xu, X. et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 4910–4915 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Morgenstern, J. P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587–3596 (1990).
Article CAS PubMed PubMed Central Google Scholar
O’Hayer, K. M. & Counter, C. M. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods Enzymol. 407, 637–647 (2006).
Article PubMed CAS Google Scholar
Norrander, J., Kempe, T. & Messing, J. Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. Gene 26, 101–106 (1983).
Article CAS PubMed Google Scholar
Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 46, W537–W544 (2018).
Article CAS PubMed PubMed Central Google Scholar
Zhang, J., Kobert, K., Flouri, T. & Stamatakis, A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30, 614–620 (2014).
Article CAS PubMed Google Scholar
Arbeithuber, B., Makova, K. D. & Tiemann-Boege, I. Artifactual mutations resulting from DNA lesions limit detection levels in ultrasensitive sequencing applications. DNA Res. 23, 547–559 (2016).
Article CAS PubMed PubMed Central Google Scholar
Rowlands, V. et al. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. Sci. Rep. 9, 12620 (2019).
Article ADS PubMed PubMed Central CAS Google Scholar
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

This work was supported by the National Institute of Cancer (R01CA94184 and P01CA203657 to C.M.C.), the National Institute of General Medicine (R35GM127062 to D.M.M.), and a pilot grant from the Duke Cancer Institute and the Nicholas School of the Environment (to C.M.C. and D.M.M.). We thank Dr. Joel Meyer and members of the Counter laboratory for helpful discussions, Dr. Ivan Spasojecic and Ping Fan from Duke Cancer Institute Pharmacokinetics & Investigational Chemotherapy Shared Resource for performing pharmacokinetic analysis of urethane and vinyl carbamate, and colleagues from Duke Cancer Institute Sequencing and Genomic Technologies Shared Resource for performing the quality check and sequencing of NGS libraries.

Author information

Authors and Affiliations

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA
Siqi Li, David M. MacAlpine & Christopher M. Counter

Authors

Siqi Li
View author publications
You can also search for this author in PubMed Google Scholar
David M. MacAlpine
View author publications
You can also search for this author in PubMed Google Scholar
Christopher M. Counter
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

S.L. performed the experiments with D.M.M. advising and C.M.C. supervising. All authors helped prepare the paper.

Corresponding author

Correspondence to Christopher M. Counter.

Ethics declarations

Competing interests

C.M.C. is a co-founder of Merlon Inc, which played no role in the design or execution of this study. The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks Georgios Stathopoulos and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Supplementary Data 6

Supplementary Data 7

Supplementary Data 8

Reporting Summary

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Li, S., MacAlpine, D.M. & Counter, C.M. Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nat Commun 11, 1800 (2020). https://doi.org/10.1038/s41467-020-15660-8

Download citation

Received: 06 September 2019
Accepted: 23 March 2020
Published: 14 April 2020
DOI: https://doi.org/10.1038/s41467-020-15660-8

This article is cited by

CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells
- Xiaochen Liu
- Fei Tian
- Yongxin Zou
Oncogene (2023)
Long-term exposure to house dust mites accelerates lung cancer development in mice
- Dongjie Wang
- Wen Li
- Samuel Bertin
Journal of Experimental & Clinical Cancer Research (2023)
The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk
- Allan Balmain
Nature Genetics (2020)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.